BRAF and diffuse midline glioma: These cases included an optic pathway/hypothalamic glioma (EOR = 64%), a focal brainstem glioma (KIAA1549-BRAF fusion pilocytic astrocytoma) (EOR = 78%), and a diffuse midline glioma with H3K27M alterations (EOR = 31%).